The future prospects of pharmacogenetics in oral anticoagulation therapy.
about
Warfarin: almost 60 years old and still causing problemsImplementing genotype-guided antithrombotic therapy.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala.Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulationCytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement.Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicineExposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosingIntegrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report.The new biology: a bridge to clinical cardiology.Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?Should all anticoagulated patients with head injury receive a CT scan? Decision-analysis modelling of an observational cohort.The changing face of oral anticoagulants.VKORC1 pharmacogenomics summary.Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.
P2860
Q24678632-271E06A9-4E86-4250-B034-3919250B135EQ33990428-36F030AC-1B55-4D58-B1B6-7B2AE2C1A3B9Q33990441-E5ADD0C4-D7BE-4D94-B811-05AC7127AABEQ34494596-C0382291-90B2-4062-ABBB-28775C9683F8Q36044022-BB3E950D-CE8C-4281-B5C3-E8663A9C16B8Q36729204-6C878205-F652-4E22-AF58-3F4A9A02D5F2Q36855608-0CD2E582-1648-403E-9933-D57E1898D49AQ36898747-020151C6-F334-4E9E-AEDA-9B3E39B68D93Q36921008-D14C079E-5B41-439E-B84D-F285F8EDA4DEQ36965475-507F9631-DB60-4BF9-8974-639F6EDED461Q37082703-61C8F136-996C-401E-82F3-90BF00CEC1BBQ37160370-96256902-0F31-442F-B1CF-6EC7CE925AA3Q37517041-8EF8F8FF-578D-4CBC-8836-A7AF1D826618Q38120951-CC47EC88-385C-4710-8AB4-89FA654F2C99Q41968877-BA509467-C833-4720-AAC3-A28185B62C5DQ50348713-4D42F1E4-FEA4-4066-BCB2-D66A88C12DCA
P2860
The future prospects of pharmacogenetics in oral anticoagulation therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@ast
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@en
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@nl
type
label
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@ast
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@en
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@nl
prefLabel
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@ast
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@en
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@nl
P2860
P1476
The future prospects of pharmacogenetics in oral anticoagulation therapy.
@en
P2093
Farhad Kamali
P2860
P304
P356
10.1111/J.1365-2125.2006.02679.X
P407
P577
2006-06-01T00:00:00Z